JBCHEPHARM JB Chemicals & Pharmaceuticals Q1 FY26 results (Apr–Jun 2025) and concall
J B Chemicals delivered a strong start to FY26, characterized by record operating margins and continued outperformance in the domestic market. While international formulations faced temporary headwinds in Russia and the US, the CDMO segment and chronic domestic portfolio provided robust growth. Management maintained its full-year guidance despite the significant strategic announcement of a controlling stake acquisition by Torrent Pharma.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY26: revenue up 9.2%, net profit up 14.5% against the same quarter last year.
| Line item | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|---|
| Revenue | 952 | 956 | 914 | 901 | 1,040 +9% |
| EBITDA | 273 | 268 | 245 | 231 | 293 +7% |
| Net profit | 173 | 173 | 156 | 150 | 198 +14% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
